uniQure (NASDAQ:QURE) Short Interest Update

uniQure (NASDAQ:QURE) was the target of a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 7,040,000 shares, a growth of 27.1% from the April 30th total of 5,540,000 shares. Based on an average daily volume of 1,750,000 shares, the short-interest ratio is currently 4.0 days. Approximately 15.2% of the company’s stock are short sold.

uniQure Trading Down 1.3%

NASDAQ:QURE opened at $14.96 on Thursday. The company has a market cap of $819.45 million, a P/E ratio of -3.02 and a beta of 0.10. The stock’s fifty day moving average price is $12.64 and its two-hundred day moving average price is $13.04. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.25. The firm had revenue of $1.57 million for the quarter, compared to analysts’ expectations of $5.93 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, analysts expect that uniQure will post -3.75 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on QURE shares. Wells Fargo & Company cut their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. Guggenheim reiterated a “buy” rating and set a $28.00 price target on shares of uniQure in a report on Monday, May 12th. Chardan Capital reiterated a “buy” rating and set a $38.00 price target on shares of uniQure in a report on Friday, May 30th. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, May 24th. Finally, Cantor Fitzgerald upgraded uniQure to a “strong-buy” rating in a research note on Monday, May 19th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and a consensus price target of $37.82.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of QURE. Twin Tree Management LP bought a new position in shares of uniQure during the fourth quarter valued at about $77,000. Mraz Amerine & Associates Inc. bought a new position in shares of uniQure during the first quarter valued at approximately $106,000. OMERS ADMINISTRATION Corp bought a new position in shares of uniQure during the first quarter valued at approximately $152,000. ADAR1 Capital Management LLC bought a new stake in shares of uniQure during the fourth quarter valued at approximately $177,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of uniQure by 9.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 969 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.